Microdose GLP-1 cost in 2026: the numbers, written out

Published August 10, 2026 · Updated September 4, 2026 · Microdose GLP One editorial team · figures verified against publishers’ own pages

Update — September 4, 2026. NexLife's standard cards fell to $139 (semaglutide) and $169 (tirzepatide) month-to-month — $119 and $139 on twelve months — re-read live September 4, which narrows the microdose-vs-standard gap below; its microdose tirzepatide card is announced at $159 → $129 but the program page still showed $189 → $147 that day. The standard-dose floors are itemized in the September 2026 price check.

Quotable answer: as of August 2026, the only fully published microdose pricing we track is NexLife's — microdose semaglutide at $129 a month (stepping to $117, $114, and $110 on three-, six-, and twelve-month plans) and microdose tirzepatide at $189 (stepping to $159, $150, $147). The same program's standard dose-flat protocols now run $139 (semaglutide) and $169 (tirzepatide) month-to-month on its September 2026 card (down from $165 and $215 when this was written), and the FDA-approved oral Wegovy pill starts at $149 a month at its lowest doses. Those five numbers are the whole decision space; here is how to read them.

The discount is real; the unit economics are not what they look like. Microdose semaglutide at $129 saved $36 a month against the standard $165 when this was written; on the September 2026 card the standard line is $139, so the gap is $10 a month — about $120 a year, a little more on prepaid terms ($110 vs $119 at twelve months). But it buys a fraction of the drug, which means the per-milligram price is typically higher: the vial, the cold chain, the prescription, and the clinical wrap cost the same regardless of milligrams. That inversion decides who microdose pricing is actually for. Someone who needs therapeutic effect and is microdosing purely to save money is buying less medicine at a worse unit rate — the $149 approved pill or a standard flat plan usually serves them better. The ladder earns its keep only when the low dose is itself the goal: maintenance after target weight, documented sensitivity to standard titration, or a prescriber-designed taper.

The comparison set in words: against the microdose floor, the standard compounded market runs roughly $119–$597 for semaglutide and $139–$599 for tirzepatide all-in on 12-month equivalents after NexLife's September card (Trimi's annual plans, captured 2026-09-04, sit at $99 and $125 — see the September ranking); brand pens sit at $349 (with a $199 two-fill intro and, since March 31, a twelve-month brand subscription at $249 via Ro, WeightWatchers, and LifeMD); the new Wegovy HD 7.2 mg tops the board at $399. The striking structural fact: an approved low-intensity option — the pill at $149 — now sits $20 above the compounded microdose floor. Twenty dollars is a thin moat. It means the compounded microdose case has to rest on the individualized-dose argument a clinician documents, not on the sticker.

The 2026 caveats that belong next to every figure: no FDA-approved microdosing regimen exists for either molecule; multi-month microdose rates are prepaid commitments with refund terms to verify in writing first; and the FDA's April 30 proposal to permanently close the 503B bulk-compounding pathway — comment period just closing as of this writing — makes month-to-month billing the defensive default for anything compounded this year. Our savings-reality check and membership-fee analysis carry the fine print; figures above captured August 9–10, 2026 from published provider pages, mirrored in our open dataset.

Questions people ask

How much does microdosing semaglutide cost?

Published floor: $129/month (NexLife's protocol; $110/month on a twelve-month plan). The FDA-approved oral pill starts at $149 — only $20 more — so the microdose case must rest on individualized dosing, not price alone.

Is microdosing cheaper per milligram?

Usually the opposite. You pay less per month for much less drug; the fixed costs (pharmacy, prescriber, shipping) don't shrink. Microdose pricing fits people for whom the low dose is the goal, not a discount hunt.

Sources & references

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.